Rapid Dose Therapeutics Corp. RDTCF
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About RDTCF
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Rapid Dose Therapeutics Corp. (OTCQB: RDTCF) is a Canadian biotechnology and drug-delivery company focused on oral fast-dissolve delivery systems for nutraceutical, pharmaceutical, and cannabis-related products. The company is best known for its proprietary QuickStrip™ technology, a thin-film oral strip designed to deliver active ingredients through rapid oral absorption. Rapid Dose Therapeutics operates within the broader health technology, life sciences, and consumer wellness industries, with activities spanning medical cannabis, nutraceuticals, and pharmaceutical delivery applications.
The company’s primary business model centers on licensing, manufacturing, and commercialization of oral thin-film products using its QuickStrip™ platform. Revenue drivers have historically included manufacturing agreements, technology licensing arrangements, and product distribution partnerships in regulated cannabis and wellness markets. Rapid Dose Therapeutics has positioned itself around differentiated delivery technology that emphasizes portability, dosing precision, rapid onset, and consumer convenience. Public filings and company disclosures indicate that the business evolved from a cannabis-focused delivery platform into a broader oral-delivery technology company pursuing pharmaceutical and wellness applications internationally.
Business Operations
Rapid Dose Therapeutics conducts operations through its proprietary QuickStrip™ oral thin-film platform, which is designed for cannabinoid formulations, vitamins, supplements, and potential pharmaceutical compounds. The company’s activities include product formulation, strip manufacturing, intellectual property development, and commercialization partnerships. Public disclosures indicate that the company has pursued both direct product sales and white-label manufacturing relationships. Its operations have primarily been concentrated in Canada, while also seeking distribution and licensing opportunities in international markets including parts of Europe, Asia, and Latin America.
The company has historically emphasized intellectual property protection and production capabilities tied to oral thin-film technologies. Rapid Dose Therapeutics has entered into various strategic relationships involving distribution, manufacturing, and regional commercialization, though some previously announced partnerships have had limited publicly disclosed financial impact. Available public information indicates that the company has explored pharmaceutical and nutraceutical applications beyond cannabis products, although commercialization progress in some sectors remains limited based on available filings and market disclosures. Data regarding the scale of current active international operations is inconclusive based on available public sources.
Strategic Position & Investments
Rapid Dose Therapeutics’ strategic direction has centered on expanding adoption of its QuickStrip™ delivery technology across regulated consumer health and pharmaceutical markets. Growth initiatives disclosed in public filings and investor materials have included international licensing arrangements, expansion into nutraceutical applications, and development of cannabinoid-based consumer products. The company has also promoted the potential for oral thin-film delivery in sectors requiring rapid absorption and precise dosing, including wellness supplements and therapeutic formulations.
The company has pursued investments in intellectual property, manufacturing infrastructure, and global commercialization partnerships rather than large-scale acquisitions. Public disclosures reference collaborations and market-entry arrangements in jurisdictions with evolving cannabis or wellness regulations. Rapid Dose Therapeutics has also highlighted emerging opportunities involving non-smokable cannabis consumption formats and alternative pharmaceutical delivery systems. However, publicly available financial disclosures indicate that commercialization and revenue scaling have remained ongoing challenges relative to larger industry peers.
Geographic Footprint
Rapid Dose Therapeutics is headquartered in Ontario, Canada, and has primarily operated from Canada while pursuing international commercial relationships. The company’s market strategy has included outreach to partners and distributors in North America, Europe, Asia, and Latin America, particularly in jurisdictions with developing medical cannabis or nutraceutical regulatory frameworks.
Public company disclosures and investor communications have referenced international licensing discussions and export-oriented strategies tied to oral thin-film technologies. While Rapid Dose Therapeutics has announced partnerships and market initiatives across multiple regions, independently verifiable information regarding the scale of sustained commercial operations outside Canada remains limited. Data concerning material international revenue contribution is inconclusive based on available public sources.
Leadership & Governance
Rapid Dose Therapeutics was founded to commercialize oral thin-film delivery technology within the cannabis and health-product sectors. The company’s leadership has generally emphasized intellectual property development, global licensing opportunities, and expansion into regulated wellness and pharmaceutical markets. Corporate strategy presented in public filings has focused on leveraging proprietary delivery technology to differentiate the company within crowded cannabis and nutraceutical industries.
Key executives and leadership figures identified in public filings and company disclosures include:
- Mark Upsdell – Chief Executive Officer
- Gerry Sklavounos – Director and former executive leadership figure
- Riaz Bandali – Former Chairman and strategic advisor roles associated with company development
- Richard Goulding – Executive and operational leadership roles disclosed in company materials
Leadership composition and executive roles have changed periodically over time, and some historical management appointments vary across public disclosures and reporting periods. Investors should review the company’s most recent public filings and corporate disclosures for current governance information.